Hepatotoxicity Related to Anti-tuberculosis Drugs in Tuberculosis and Tuberculosis-HIV Coinfection Patients
DOI:
https://doi.org/10.36408/mhjcm.v9i1.650Keywords:
hepatotoxicity, HIV, antituberculosis drugs, tuberculosisAbstract
BACKGROUND : The side effect of antituberculosis drugs that is toxic to liver cells, called hepatotoxic, needs to be a concern in the treatment of tuberculosis. The presence of these unwanted side effects poses a challenge in treatment because it can lead to discontinuation oh therapy or a change in regimen. Coinfection with HIV is also thought to increase the potential for hepatotoxicity of antituberculosis drugs.
OBJECTIVE: This study aims to determine the incidence of hepatotoxicity of antituberculosis drugs in patients with tuberculosis and tuberculosis-HIV coinfection.
METHOD : This study is an observational study with a cross sectional design, which was conducted in one of the hospitals in Samarinda City. Sources of research data came from patient medical record in 2018 – 2020. There was 53 tuberculosis patients and 53 tuberculosis-HIV coinfection patients. Differences in live enzyme values (AST and ALT) and severity in the two groups were analyzed by Mann-Whitney and Chi-Square tests.
RESULT : The average value of AST and ALT in tuberculosis-HIV coinfection patients were higher than patients without HIV infection, which is AST 127,1 µ/L and ALT 100,7 µ/L. The highest degree of severity experienced by the patient was grade 3 (severe hepatotoxicity). Tuberculosis-HIV coinfection patients with grade 3 severity were 22,6% and tuberculosis patients were 9,4%. The values of liver enzymes and the severity of hepatotoxicity in the two groups of patients were statistically significant with p value < 0,05.
CONCLUSION : Tuberculosis-HIV coinfection patients tend to have a higher incidence of hepatotoxicity related to antituberculosis drugs than those without HIV infection.
Downloads
References
Campo M, Kawamura L. Patient Education - Tuberculosis: Information Series. Am J Respir Crit Care Med [Internet]. 2017;195:7–8. Available from: www.thoracic.org
World Health Organization. Global Tuberculosis Report 2020. Geneva: World Health Organization; 2020.
Kementerian Kesehatan Republik Indonesia. Buku Petunjuk TB-HIV untuk Petugas Kesehatan. Jakarta: Direktorat Jenderal Pencegahan dan Pengendalian Penyakit Kementerian Kesehatan RI; 2016.
Kementerian Kesehatan Republik Indonesia. Strategi Nasional Penanggulangan Tuberkulosis di Indonesia 2020-2024. Pertemuan Konsolidasi Nasional Penyusunan STRANAS TB. Jakarta: Direktorat Jenderal Pencegahan dan Pengendalian Penyakit Kementerian Kesehatan RI; 2020.
Soedarsono, Riadi ARW. Tuberculosis Drug-Induced Liver Injury. J Respirasi. 2020;6(2):49–54.
Zeleke A, Misiker B, Yesuf TA. Drug-induced Hepatotoxicity Among TB/HIV Co-infected Patients in a Referral Hospital, Ethiopia. BMC Res Notes [Internet]. 2020;13(2):1–5. Available from: https://doi.org/10.1186/s13104-019-4872-1
David S, Hamilton JP. Drug-induced Liver Injury. US Gastroenterol Hepatol Rev. 2010;1(6):73–80.
Banjuradja I, Singh G. Mekanisme Hepatotoksisitas dan Tatalaksana Tuberkulosis pada Gangguan Hati. Indones J Chest. 2020;7(2):55–64.
Clarasanti I, Wongkar MCP, Waleleng BJ. Gambaran Enzim Transaminase pada Pasien Tuberkulosis Paru yang Diterapi dengan Obat-obat Anti Tuberkulosis di RSUP Prof. Dr. R. D. Kandou Manado. e-CliniC. 2016;4(1):1–6.
Enoh JE, Cho FN, Manfo FP, Ako SE, Akum EA. Abnormal Levels of Liver Enzymes and Hepatotoxicity in HIV-Positive, TB, and HIV/TB-Coinfected Patients on Treatment in Fako Division, Southwest Region of Cameroon. Biomed Res Int. 2020;1–9.
Mo P, Zhu Q, Teter C, Yang R, Deng L, Yan Y, et al. Prevalence, Drug-induced Hepatotoxicity, and Mortality Among Patients Multi-infected with HIV, Tuberculosis, and Hepatitis Virus. Int J Infect Dis. 2014;28:95–100.
Sumantri AF, Djumhana A, Wisaksana R, Sumantri R. Insidensi dan Karakteristik Hepatotoksisitas Obat Antituberkulosis pada Penderita Tuberkulosis dengan dan tanpa Infeksi HIV. Vol. 3, Global Medical & Health Communication (GMHC). 2015. p. 78.
Ramappa V, Aithal GP. Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management. J Clin Exp Hepatol. 2013;3(1):37–49.
Yimer G, Gry M, Amogne W, Makonnen E, Habtewold A, Petros Z, et al. Evaluation of Patterns of Liver Toxicity in Patients on Antiretroviral and Anti-Tuberculosis Drugs: A Prospective Four Arm Observational Study in Ethiopian Patients. PLoS One. 2014;9(4):1–10.
Chang TE, Huang YS, Su WJ, Perng CL, Huang YH, Hou MC. The Role of Regular Liver Function Monitoring in Antituberculosis Drug-induced Liver Injury. J Chinese Med Assoc. 2019;82(7):535–40.
Wu S, Xia Y, Lv X, Zhang Y, Tang S, Yang Z, et al. Effect of Scheduled Monitoring of Liver Function During Anti-Tuberculosis Treatment in a Retrospective Cohort in China. BMC Public Health. 2012;12(454):1–7.
Kementerian Kesehatan Republik Indonesia. Peraturan Menteri Kesehatan Republik Indonesia Nomor 67 Tahun 2016 tentang Penanggulangan Tuberkulosis. 2016;
Lima MFS, Melo HRL. Hepatotoxicity Induced by Antituberculosis Drugs Among Patients Coinfected with HIV and Tuberculosis. Artigo. 2012;28(4):698–708.
Additional Files
Published
How to Cite
Issue
Section
Citation Check
License
Copyright (c) 2022 Medica Hospitalia : Journal of Clinical Medicine
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Copyrights Notice
Copyrights:
Researchers publishing manuscrips at Medica Hospitalis: Journal of Clinical Medicine agree with regulations as follow:
Copyrights of each article belong to researchers, and it is likewise the patent rights
Researchers admit that Medica Hospitalia: Journal of Clinical Medicine has the right of first publication
Researchers may submit manuscripts separately, manage non exclusive distribution of published manuscripts into other versions (such as: being sent to researchers’ institutional repository, publication in the books, etc), admitting that manuscripts have been firstly published at Medica Hospitalia: Journal of Clinical Medicine
License:
Medica Hospitalia: Journal of Clinical Medicine is disseminated based on provisions of Creative Common Attribution-Share Alike 4.0 Internasional It allows individuals to duplicate and disseminate manuscripts in any formats, to alter, compose and make derivatives of manuscripts for any purpose. You are not allowed to use manuscripts for commercial purposes. You should properly acknowledge, reference links, and state that alterations have been made. You can do so in proper ways, but it does not hint that the licensors support you or your usage.
